Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors

被引:150
作者
Proctor, NJ [1 ]
Tucker, GT [1 ]
Rostami-Hodjegan, A [1 ]
机构
[1] Univ Sheffield, Royal Hallamshire Hosp, Clin Sci Div S, Sheffield S10 2JF, S Yorkshire, England
关键词
D O I
10.1080/00498250310001646353
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. Recombinantly expressed human cytochromes P450 (rhCYPs) have been underused for the prediction of human drug clearance (CL). 2. Differences in intrinsic activity (per unit CYP) between rhCYP and human liver enzymes complicate the issue and these discrepancies have not been investigated systematically. We define intersystem extrapolation factors (ISEFs) that allow the use of rhCYP data for the in vitro - in vivo extrapolation of human drug CL and the variance that is associated with interindividual variation of CYP abundance due to genetic and environmental effects. 3. A large database (n = 451) of metabolic stability data has been compiled and used to derive ISEFs for the most commonly used expression systems and CYP enzymes. 4. Statistical models were constructed for the ISEFs to determine major covariates in order to optimize experimental design to increase prediction accuracy. 5. Suggestions have been made for the conduct of future studies using rhCYP to predict human drug clearance.
引用
收藏
页码:151 / 178
页数:28
相关论文
共 133 条
[101]   CYTOCHROME P450-DEPENDENT METABOLISM OF ACETAMINOPHEN IN 4 HUMAN TRANSGENIC LYMPHOBLASTOID CELL-LINES [J].
SNAWDER, JE ;
ROE, AL ;
BENSON, RW ;
CASCIANO, DA ;
ROBERTS, DW .
PHARMACOGENETICS, 1994, 4 (01) :43-46
[102]  
Störmer E, 2000, J PHARMACOL EXP THER, V295, P793
[103]   The role of the CYP2C9-Leu(359) allelic variant in the tolbutamide polymorphism [J].
SullivanKlose, TH ;
Ghanayem, BI ;
Bell, DA ;
Zhang, ZY ;
Kaminsky, LS ;
Shenfield, GM ;
Miners, JO ;
Birkett, DJ ;
Goldstein, JA .
PHARMACOGENETICS, 1996, 6 (04) :341-349
[104]  
Taguchi M, 2001, RES COMMUN MOL PATH, V109, P53
[105]   CYP2C9 Ile359 and Leu359 variants:: enzyme kinetic study with seven substrates [J].
Takanashi, K ;
Tainaka, H ;
Kobayashi, K ;
Yasumori, T ;
Hosakawa, M ;
Chiba, K .
PHARMACOGENETICS, 2000, 10 (02) :95-104
[106]  
Tang CY, 2000, DRUG METAB DISPOS, V28, P567
[107]   CAFFEINE AS A PROBE FOR HUMAN CYTOCHROMES-P450 - VALIDATION USING CDNA-EXPRESSION, IMMUNOINHIBITION AND MICROSOMAL KINETIC AND INHIBITOR TECHNIQUES [J].
TASSANEEYAKUL, W ;
MOHAMED, Z ;
BIRKETT, DJ ;
MCMANUS, ME ;
VERONESE, ME ;
TUKEY, RH ;
QUATTROCHI, LC ;
GONZALEZ, FJ ;
MINERS, JO .
PHARMACOGENETICS, 1992, 2 (04) :173-183
[108]  
TASSANEEYAKUL W, 1993, J PHARMACOL EXP THER, V265, P401
[109]   VALIDATION OF 4-NITROPHENOL AS AN IN-VITRO SUBSTRATE PROBE FOR HUMAN LIVER CYP2E1 USING CDNA EXPRESSION AND MICROSOMAL KINETIC TECHNIQUES [J].
TASSANEEYAKUL, W ;
VERONESE, ME ;
BIRKETT, DJ ;
GONZALEZ, FJ ;
MINERS, JO .
BIOCHEMICAL PHARMACOLOGY, 1993, 46 (11) :1975-1981
[110]   Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism [J].
Thummel, KE ;
OShea, D ;
Paine, MF ;
Shen, DD ;
Kunze, KL ;
Perkins, JD ;
Wilkinson, GR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (05) :491-502